News

Sernova and Dr. Mark Poznansky, M.D., Ph.D., Associate Professor of Medicine at Harvard Medical School and Director of the Vaccine and Immunotherapy Center at Massachusetts General Hospital will

The study, published in the American Journal of Psychiatry in Advance, included a total of 130 outpatients with bipolar I disorder and cocaine dependence, who received either Cognizin

The deal is subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR). Allergan will buy these rights for an

The transaction will enhance Hi-Tech’s leading Sports Nutrition and Weight Loss arsenal and expand its position as the leader in Diet & Energy products in the United States.

The STRIVE trial is designed to evaluate the safety and efficacy of the vaccine to determine if it prevents postoperative invasive S. aureus infections in patients undergoing elective

The closing of the stock purchase transaction is subject to customary closing conditions for a transaction of this nature and approval of the Toronto Stock Exchange. Under the

"We are excited to collaborate with UCSF, a world-renowned academic research institution," said Jonathan Lim, M.D., Chairman and CEO of Ignyta. "The focus on melanoma in this study

RHB-104 is a proprietary and potentially groundbreaking antibiotic combination therapy in oral capsule formulation, with potent intracellular, anti-mycobacterial and anti-inflammatory properties. The MAP US study is the first

FCS is a rare genetic disease characterized by extremely high triglyceride levels and risk of pancreatitis. In a Phase 2 study published in the NEJM in December 2014,